• Fucoidan in Cancer and Liver Injury Models: Applied Workflow

  2026-05-14

  Fucoidan, a sulfated α-L-fucan from brown seaweed, excels as an anticancer polysaccharide and in protecting against chemotherapy-induced liver injury. This article offers actionable protocols, troubleshooting guidance, and workflow enhancements grounded in recent advances and APExBIO's high-purity preparation.

• PNU 74654: Advanced Wnt Pathway Inhibition for Precision Res

  2026-05-14

  Explore how PNU 74654, a potent Wnt signaling pathway inhibitor, enables precise modulation of cell fate in cancer and stem cell research. This article uniquely integrates mechanistic insights with practical assay guidance, grounded in recent landmark findings.

• FLOT1-FOSL2-EphA2 Axis Regulates Microglial Polarization in

  2026-05-13

  This study reveals how the interaction between FLOT1 and FOSL2 upregulates EphA2 transcription, activating p38/MAPK signaling to drive pro-inflammatory microglial polarization in Alzheimer's disease. Targeting this pathway reduced neuroinflammation and improved cognitive outcomes in APP/PS1 mouse models, highlighting a promising therapeutic target for modulating microglial function in neurodegenerative disease.

• Proteoform-Specific Drug Interactions in Native Cell Signali

  2026-05-13

  This study pioneers native top-down mass spectrometry to directly map proteoform-specific protein–ligand interactions within unmodified membrane environments. The findings reveal how protein modifications such as alternative splicing and lipidation shape both physiological signaling and off-target drug binding, with implications for the precision of PDE5 inhibitor design.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-05-12

  This study pioneers the direct analysis of proteoform-specific drug interactions within native membrane environments, leveraging advanced mass spectrometry to resolve how post-translational modifications and alternative splicing impact the selectivity and off-target effects of small-molecule inhibitors. The findings provide a technical foundation for rational drug development with improved safety and efficacy profiles.

• 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine f

  2026-05-12

  This scenario-driven article addresses common laboratory challenges in α2-adrenergic receptor signaling and post-surgery osteosarcoma recurrence research, demonstrating how 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (SKU B3465) from APExBIO ensures data-backed reproducibility and workflow confidence. Researchers will find actionable, literature-grounded guidance for optimizing immune rejection modulation assays with validated performance parameters.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Burden

  2026-05-11

  The referenced study establishes a phenotypic screening approach to identify and deploy small molecule inhibitors that downregulate SPP1 in tumor-associated macrophages (TAMs), culminating in significant tumor remissions in murine models. These findings provide direct evidence that SPP1 is not only a biomarker but also a viable therapeutic target for modulating the tumor microenvironment.

• Redefining In Vitro Drug Response Metrics in Cancer Research

  2026-05-11

  Schwartz's dissertation systematically dissects the limitations of standard in vitro metrics for anti-cancer drug evaluation, distinguishing between relative viability and fractional viability. The work advances the understanding of how proliferation inhibition and cell death contribute to measured drug responses, informing more precise experimental design and data interpretation in preclinical oncology.

• KX2-391 Dihydrochloride: Applied Protocols Across Oncology &

  2026-05-10

  KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) uniquely combines potent Src kinase inhibition with tubulin polymerization blockade and HBV transcription suppression, enabling multifaceted research workflows. Evidence-driven assay design and troubleshooting tips help maximize reproducibility and specificity in oncology, virology, and neurotoxin studies.

• Proteoform-Specific Drug Interactions in Native Membrane Sig

  2026-05-09

  This study pioneers the direct analysis of proteoform-specific interactions in native membrane environments, revealing how post-translational modifications and alternative splicing impact drug targeting. Using advanced mass spectrometry, the authors uncover differential off-target binding of PDE5 inhibitors, including Vardenafil, to distinct proteoforms, with implications for therapeutic selectivity and safety.

• Phosphatase Inhibitor Cocktail 3: Precision in Phosphoprotei

  2026-05-08

  Unlock reliable protein phosphorylation preservation with Phosphatase Inhibitor Cocktail 3 (100X in DMSO), a robust serine/threonine phosphatase inhibitor for advanced signaling and phosphoprotein workflows. Learn how optimized protocols and troubleshooting tips can elevate your Western blot and phosphoprotein analysis, with APExBIO as your trusted partner.

• RNASEH1-AS1 as a Prognostic Biomarker in Hepatocellular Carc

  2026-05-08

  This study identifies the long non-coding RNA RNASEH1-AS1 as a clinically relevant biomarker and oncogenic target in hepatocellular carcinoma (HCC). Comprehensive bioinformatic and experimental analyses reveal RNASEH1-AS1 as an independent predictor of poor prognosis, highlighting its role in tumor progression and interaction with immune infiltrates.

• IPCRL1 Knockdown Attenuates Myocardial Ischemia/Reperfusion

  2026-05-07

  This study identifies the long noncoding RNA IPCRL1 as a key regulator in myocardial ischemia/reperfusion injury (MIRI). By elucidating the IPCRL1/miR-185-3p/JIP3 axis and its modulation of the JNK pathway, the research highlights a novel molecular target for cardioprotection.

• Scenario-Based Solutions with TUNEL Apoptosis Detection Kit

  2026-05-07

  This article delivers scenario-driven guidance for researchers using the TUNEL Apoptosis Detection Kit (DAB) (SKU K2271), addressing real-world laboratory challenges in apoptosis and DNA fragmentation analysis. Through practical Q&A and protocol recommendations, we demonstrate how SKU K2271 supports reproducible, high-sensitivity detection in diverse samples, grounded in evidence and best practices.

• Optimizing Apoptosis Assays with A-1331852 (SKU B6164): Scen

  2026-05-06

  This article provides a scenario-driven, evidence-based guide to leveraging A-1331852 (SKU B6164) as a high-affinity, selective BCL-XL inhibitor in apoptosis research and cancer studies. It addresses common laboratory challenges—such as assay sensitivity, workflow reproducibility, and vendor reliability—using real experimental contexts and literature-backed recommendations. Readers gain actionable strategies to improve data quality and experimental outcomes with A-1331852.

15252 records 1/1017 page Next 12345 下5页 Last page